Growth Hormone Replacement Therapy: Transition from Adolescence to Adulthood by Geffner, Mitchell E.
J Clin Res Ped Endo 2009;1(5):205-208 
DOI: 10.4274/jcrpe.v1i5.205
Mitchell E. Geffner
Saban Research Institute, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, USA
Address for Correspondence
Mitchell E. Geffner, Childrens Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA
Phone: +00 323-361-7032 Fax: +00 323-361-1350 E-mail: mgeffner@chla.usc.edu
© Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing. All rights reserved.
Growth Hormone Replacement Therapy: 
Transition from Adolescence to Adulthood
Review
205
Introduction
Until approximately 15 years ago, growth hormone (GH) 
treatment was confined mostly to children with GH deficiency
(GHD). In 1997, GH treatment was first approved in the United
States (US) for use in adults with GHD, either acquired in 
childhood or de novo in adults with hypothalamic-pituitary 
disease. Most recently, there has been increasing study of 
children previously diagnosed with GHD who have reached ol-
der adolescent age in terms of persistence of the original 
diagnosis, optimization of GH retesting and dosing, and 
evidence underscoring need for persistence of GH treatment.
As such, this period of time between childhood and adulthood
has been dubbed the “transition period” which refers to a 
broad set of physical and psychosocial changes, which are 
arbitrarily defined as starting in puberty and ending with full
adult maturation. As it relates to GHD, this period is defined as
the window of time in which a child no longer requires GH for
sustaining linear growth, but does so for ongoing treatment of
non-statural, i.e., metabolic, reasons. This usually suggests a
period from the mid-to-late teenage years until 6-7 years after
reaching adult height. 
Adult GH Deficiency Syndrome
The need for GH treatment of GH-deficient adults is based
on two general pieces of evidence. First, untreated adults
with proven severe GHD manifest what has come to be
known as the adult GHD syndrome. It is characterized by: (i)
abnormal body composition (with increased fat mass and 
decreased lean body or muscle mass); (ii) decreased bone 
mineral density (with increased fracture risk possibly 
exacerbated by sex steroid deficiency and/or over-treatment
with glucocorticoids); (iii) reduced exercise capacity (perhaps
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composition); (iv) abnormal serum lipids (including increased
total and LDL cholesterol, increased triglycerides, and 
decreased HDL cholesterol); and (v) impaired quality-of-life
(including social isolation, depression, and diminished sense
of well-being) as assessed by standardized questionnaire.
These findings (collated from 9 studies) are summarized in
the Table, which shows the effects of severe GHD in young
adults in whom GH treatment had been discontinued for an
average of 8 years after attainment of final height (1-9). 
Second, the improvement of the above constellation of
abnormalities with GH treatment (at relatively low doses
compared to those required for statural growth in childhood)
in double-blinded, placebo-controlled studies cemented the
existence of the adult GHD syndrome. 
Persistence of Childhood GH Deficiency
With the approval of GH treatment in the US by the FDA to
treat adult GHD, studies commenced to assess the magnitude
of newly diagnosed GHD or re-assess the severity of 
previously diagnosed disease. Surprisingly (at first), the “pass
rate” (i.e., no evidence of GHD) on re-testing of older 
adolescents previously diagnosed with childhood GHD was
strikingly high. In those previously diagnosed as having had 
idiopathic, isolated GHD, as many as 67% of subjects now
passed their re-test, i.e., had peak GH values >10 mg/L 
following stimulation. In fact, similar results have recently 
been reported when retesting was done at the start of puberty
(10). However, in the presence of multiple hormone 
deficiencies and/or clear-cut evidence of organic hypothalamic-
pituitary disease, persistence of severe GHD into adulthood
was >90% (11). While an entity of transient GHD in childhood
might exist, this difference in results could more likely reflect
variations in stimulation testing protocols, reproducibility of GH
test results, methodological factors in GH assays, failure to use
sex-steroid priming prior to provocation, and concomitant 
effects of nutrition.
GH Re-Testing: Whom?
Thus, re-evaluation of the GH-IGF-I axis should be performed
in all adolescents reaching the transition period (if not at start
of puberty) who had been previously diagnosed with idiopathic
(normal head MRI), isolated (no other hypothalamic-
pituitary hormone deficiencies) GH deficiency. Patients with a
high likelihood of having permanent GHD are those who have
multiple pituitary hormone deficiencies (MPHD) and a low 
serum IGF-I concentration in conjunction with one or more of
the following: (i) a clinically and/or radiologically confirmed 
congenital mid-line abnormality involving the sellar or suprasellar
region; (ii) known acquired hypothalamic-pituitary disease, e.g.
due to a craniopharyngioma; (iii) prior surgery for lesions 
directly affecting the hypothalamic-pituitary region or high-
dose radiotherapy for malignant disease located in the 
hypothalamic-pituitary region; or (iv) a proven genetic/molecular
defect involving the proximal portion of the GH-IGF-I axis. If
children in these high-risk categories have a low serum IGF-I 
level after short-term discontinuation of GH treatment, this
should suffice as documentation of persistent GHD (12). 
GH Retesting: When?
Since longstanding GH treatment may well blunt the 
response to acute GH stimulation testing by having caused a
chronic increase in the serum level of IGF-I, a GH-free 
“wash-out” period is recommended prior to retesting. 
However, the shortest interval off GH therapy that would 
allow valid re-testing of the GH axis remains unknown. 
Proposed intervals between cessation of GH treatment and
re-testing of the GH axis generally range from 1 to 3 months
(13). Optimization of all other hormone therapy doses is 
critical for accurate interpretation of GH testing, especially
thyroid hormone. 
GH Retesting: How?
This process should start with measurement of a serum
IGF-I concentration which, if ≥50th %ile for age and gender,
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T Ta ab bl le e. .   Effects of Severe GH Deficiency in Young Adults*
M Me ea as su ur re em me en nt t C Ch ha an ng ge e   v vs s   c co on nt tr ro ol ls s n n
Subcutaneous fat mass +75% 46
Intra-abdominal fat mass +85% 46
Muscle mass -20% 46
Bone mineral density -10% 100
Serum LDL cholesterol +20% 64
Cognitive function -15% 48
Myocardial function Abnormal 18
*Note that >90% of the subjects were male with an average age of 28
years and an average adult height of 165 cm (From Reference Number 1).
Figure. GHD:  Schema for reassessing the GH-IGF-I axis during the
transition period
Clinically and/or radiologically con-
firmed congenital mid-line defect
involving the sellar or suprasellar
region; known acquired hypothala-
mic-pituitary disease, e.g. due to a
craniopharyngioma; (prior surgery
for lesions directly affecting the
hypothalamic-pituitary region or
high-dose radiotherapy for malig-
nant disease located in the hypo-
thalamic-pituitary region; or a
proven genetic/molecular defect
involving the proximal portion of
the GH-IGF-I axis
Previous diagnosis of idiopathic
(normal head MRI), isolated (no
other hypothalamic-pituitary hor-
mone deficiencies) GH deficiency
Discontinue GH for 1-3 months
Screen with serum IGF-I 
IGF-I >50
th centile
Consider 
re-evaluating in
2-5 years based
on clinical sce-
nario  
IGF-I <50
th centile
Formal GH
testing
Low serum IGF-I
No GH testing required 
Individuals with childhood-onset GHD who have attained adult height
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↓effectively rules out persistent GHD which is the expected
outcome in those with idiopathic, isolated GHD. If the IGF-I
level is ≤50th% ile in individuals with a high likelihood of 
persistent GHD (see “GH Testing: Whom”), formal GH 
testing need not be done, but, in those with a presumed low
likelihood, i.e., those with a prior diagnosis of idiopathic, 
isolated GHD, formal retesting is mandatory (13) (Figure).
In childhood, GHD in the US has traditionally been 
defined as all stimulated GH values <10 mg/L using traditional
stimuli such as clonidine, carbidopa, glucagon, arginine,
and/or insulin. In adults, insulin hypoglycemia is the test of
choice to diagnose GH deficiency, with severe deficiency 
arbitrarily defined as a peak GH of <3 mg/L. However, as this
test is labor-intensive, expensive, and not without risk, 
internist-endocrinologists developed alternative combination
protocols including GH-releasing hormone (GHRH)/arginine
(preferred in the US) and GHRH/pyridostigmine (used in 
Europe). Because of the potency of these combination 
stimuli relative to insulin, severe GHD was defined as a peak
GH of <9 mg/L. However, GHRH is no longer available in the
US, so additional testing protocols for adults need to be 
devised (14).
For diagnosis of GHD during the transition period, the 
proposed cut-off is a GH level of <5 mg/L, intermediate 
between the criteria for childhood and adult GHD. 
Unfortunately, during this period, the optimal means of GH
retesting is unknown. Although not well studied in this age
group, the preferred tests are insulin or glucagon.
In ultimately deciding what is the appropriate GH cut-off
to diagnose GHD during the transition period, it is important
to consider the normal gender-, age- and/or pubertal-adjusted
pattern of GH secretion (recognizing that the greatest 
amount of GH is produced during puberty). The effect of
BMI (e.g., as reflected by waist-to-hip ratio) must also be 
taken into account as GH secretion (at all ages) decreases
with increasing visceral adiposity (15).
GH Treatment: Why?
The bulk of existing data reinforce the need for GH 
treatment of adults with persistent GHD previously 
diagnosed in childhood. Supporting this recommendation
are several key studies. First, in a 2-year study of GH 
resumption (comparing two doses, 12.5 and 25 μg/kg/day
vs. placebo) during the transition period among 64 individuals
previously treated for childhood GHD and off GH for at 
least 1 year, bone mineral density of the spine was shown
to increase significantly in both treatment arms after 2 
years of treatment with no significant improvement in the
placebo group (16).
Second, 149 older adolescents (mean age 19 years)
with severe GHD (80% with MPHD) were randomized to
receive one of two different GH dosages or placebo for 2
years  (17). In both treatment arms, significant favorable 
differences in body composition were found, i.e., increased
lean body mass and decreased fat mass, with absence of
disturbances in LDL and HDL concentrations. These 
investigators concluded that, when two-dimensional 
statural growth is complete, children with GHD still need
GH to achieve three-dimensional development to target
adult body composition, and that a long period off GH can
be detrimental.
Third, using combined KIGS (Pfizer International
Growth)-KIMS (Pfizer International Metabolic) pharmaco-
epidemiological databases (18), data from 324 patients (200
males), initially followed in KIGS and then re-enrolled into
KIMS, with a mean duration between the end of pediatric
and the resumption of adult GH treatment of 4.5±3.1 yr,
were analyzed. The results showed that serum IGF-I SDS in
adults was related to the severity of GHD during childhood
and that a longer period between cessation of GH 
treatment at the completion of linear growth and 
recommencement of GH treatment was associated with
statistically significant detrimental lipid profiles and poorer
quality-of-life. The investigators concluded that pediatricians
should tailor GH treatment not only for its effect on 
childhood GHD, but also for future health in adulthood. 
Fourth, in another study of 58 adolescents with 
childhood-onset GHD, a large proportion of whom had 
isolated idiopathic GHD, investigators found contrasting 
observations  (19). These individuals were randomized to 
receive either GH or placebo for 2 years after retesting at
study start confirmed the diagnosis of GHD. After 2 years, no
difference existed between the two groups with regard to 
lipid and carbohydrate metabolism, body composition, bone
mineral density, cardiac function, muscle strength, or 
quality-of-life. Thus, these investigators concluded that GH
can safely be discontinued for at least 2 years after 
attainment of near-adult height.
GH Dosing During Transition: How Much?
During puberty, adolescents with GHD typically receive
GH in a wide range of doses (usually between 1.25 and 2.5
mg/day for a child weighing 50 kg, although the FDA has 
approved doses as high as 5 mg/day in the US). In the 
transition period, patients should have their GH dose 
lowered or, if already discontinued, restarted between 
0.2-0.5 mg/day with (upward) adjustments made on the basis
of age- and gender-adjusted serum IGF-I levels, estrogen
status, clinical response, and lack of side effects (12).
Summary and Conclusions
A schema by which to begin the re-evaluation process
for adolescents/young adults previously diagnosed with
childhood-onset GHD can be found in the Figure and can
serve as the basis for transitioning the pediatric patient to
adult care.
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period are bone mineral accretion and serum IGF-I 
concentrations. In patients with idiopathic, isolated GHD,
GH re-testing should be performed. In patients with MPHD
and a low serum IGF-I concentration, there is generally no
need to re-test GH secretory status and GH should be 
continued at a lower dose than previously used for height
achievement. Even with confirmed severe GHD, if the 
serum IGF-I concentration and bone density are normal,
there appears to be no negative impact of treatment 
discontinuation for 2 years.
While the benefits and risks of GH treatment in adults
have been extensively studied over the past 15 years, 
criteria for who should be tested, optimal method(s) of 
testing, and time off GH prior to retesting of GH axis in 
young adults with childhood-onset GHD during the transition
period remain much less well-characterized. Retesting of
other hypothalamic-pituitary axes for which treatment had
or had not been initiated in childhood has received even
less attention, but possibilities of spontaneous normalization
(e.g., thyroid function) or late drop-out (e.g., adrenal function)
must be considered. Finally, it is important to remember
that, during the transition period in teenagers with GHD or
more extensive hypopituitarism, there must be initiation of
a thoughtful and seamless plan for transfer of care to an 
internist-endocrinologist with expertise in management of
hypothalamic-pituitary disease in young adults (20).
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